Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Therapy in R/R AML

In this “Clinical Trials & Observations” report/visual abstract from the pages of Blood Advances (ASH), the authors focus on two key points: 1) In patients with R/R AML, venetoclax combination therapy resulted in responses in 31% of patients and a median OS of 6.1 months, and 2) NPM1 mutations predicted higher response rates; adverse cytogenetics and mutations in TP53, KRAS/NRAS, and SF3B1 predicted worse OS.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form